CONTEXT THERAPEUTICS INC. Debt Conversion, Converted Instrument, Amount
CONTEXT THERAPEUTICS INC. (CNTX) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2023-03-22
- CONTEXT THERAPEUTICS INC. debt conversion, converted instrument, amount for the quarter ending 2022-12-31 was $0.00.
- CONTEXT THERAPEUTICS INC. debt conversion, converted instrument, amount for the quarter ending 2022-09-30 was $0.00.
- CONTEXT THERAPEUTICS INC. debt conversion, converted instrument, amount for the quarter ending 2022-06-30 was $0.00.
- CONTEXT THERAPEUTICS INC. debt conversion, converted instrument, amount for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- CONTEXT THERAPEUTICS INC. debt conversion, converted instrument, amount for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- CONTEXT THERAPEUTICS INC. debt conversion, converted instrument, amount for fiscal 2021 was $5.87M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $0.00 derived: sum of 3 quarters · filed 2023-03-22 | $0.00 10-K · filed 2023-03-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-03-22 | $0.00 derived: sum of 4 quarters · filed 2023-03-22 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $0.00 derived: sum of 3 quarters · filed 2023-03-22 | $0.00 derived: sum of 4 quarters · filed 2023-03-22 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $0.00 derived: sum of 3 quarters · filed 2023-03-22 | $5.87M 10-K · filed 2023-03-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $5.87M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $5.87M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $5.87M 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |